People In Brief
This article was originally published in The Gray Sheet
Executive Summary
Edwards expands D.C. presence: Dirksen Lehman and Barry Liden are heading up Edwards Lifesciences' Washington, D.C., government affairs office, the firm announces Oct. 26. Lehman, the new VP-government affairs, joins Edwards from consulting firm Clark & Weinstock, where he led the health care practice. He previously served as special assistant to the President for legislative affairs as the White House's primary liaison to the Senate for health care issues (1"The Gray Sheet" Feb. 5, 2001, p. 24). Liden, director for government affairs, joined the firm in 2002. He previously was director of external communications and most recently directed the firm's state government affairs operations from the Irvine, Calif., headquarters. Edwards says the D.C. office will support the company's growing role in AdvaMed, of which CEO Michael Mussallem becomes chairman in 2008 (2"The Gray Sheet" March 12, 2007, In Brief)
You may also be interested in...
Dirksen Lehman
President Bush announces Jan. 30 his intention to name Senate Health Committee staff health counsel Lehman as a special assistant for legislative affairs for the Senate. Lehman will work as one of the Senate lobbyists in the White House Office of Legislative Affairs, reporting to chief Senate lobbyist Ziad Ojakli, former chief of staff to Sen. Paul Coverdell (R-Ga.). Before joining the Health Committee staff in 1999, Lehman was with Washington lobbying firm Williams & Jensen. The Health Committee has not yet named a replacement
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.